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BoBACKGROUND Point-by-point catheter ablation is an established treatment for drug-refractory paroxysmal atrial
ﬁbrillation (PAF). However, it is time consuming, requires excellent technique to achieve complete pulmonary vein (PV)
isolation, and is associated with severe complications.
OBJECTIVES The purpose of this study was to evaluate the safety and effectiveness of a HotBalloon ablation (HBA)
compared with antiarrhythmic drug therapy (ADT) for the treatment of PAF.
METHODS A prospective multicenter randomized controlled study was conducted in Japan. Patients with symptomatic
PAF refractory to antiarrhythmic drugs (Class I to IV) were randomized to HBA or ADT at a 2:1 ratio and assessed for
effectiveness in a comparable 9-month follow-up period.
RESULTS A total of 100 patients in the HBA group and 43 patients in the ADT group received treatment at 17 sites.
HBA procedure produced acute complete PV isolation in 98.0% (392 of 400) of the PVs and in 93.0% (93 of 100) of pa-
tients in the HBA group. The chronic success rates after the 9-month effective evaluation period were 59.0% in the HBA
group (n¼ 100) and 4.7% in the ADT group (n¼ 43; p<0.001). The incidence of major complications was 11.2% (15 of 134
patients). The incidences of PV stenosis (>70%) and transient phrenic nerve injury were 5.2% and 3.7%, respectively. The
mean ﬂuoroscopy time was 49.4  26.6 min (n ¼ 134), and the mean procedure duration was 113.9  31.9 min (n ¼ 133).
CONCLUSIONS This study demonstrates the superiority of HBA compared with ADT for treatment of patients with
PAF, and a favorable safety proﬁle. (J Am Coll Cardiol 2016;68:2747–57) © 2016 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
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AADs = antiarrhythmic drugs
ADT = antiarrhythmic drug
therapy
AF = atrial ﬁbrillation
HBA = HotBalloon ablation
LA = left atrium
MJC = major complication
PAF = paroxysmal atrial
ﬁbrillation
PV = pulmonary vein
SAE = serious adverse event
SF-36v2 = 36-item Short-Form
Health Survey Version 2 Japan
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2748P oint-by-point catheter ablation isan established treatment for drug-refractory paroxysmal atrial ﬁbrilla-
tion (PAF) (1,2). However, it is time
consuming, requires excellent technique to
achieve complete pulmonary vein (PV) isola-
tion, and is associated with severe complica-
tions (1–4). An ideal catheter ablation
method to treat atrial ﬁbrillation (AF) would
be quicker, less technically difﬁcult, mini-
mize collateral damage, and provide durable
PV isolation. A radiofrequency HotBalloon
catheter (Central Illustration) has been devel-
oped to overcome several of these limitations
(5,6). The balloon membrane material is
elastic and compliant, so it ﬁts the variablePV anatomy (7). Consequently, this clinical study was
undertaken to evaluate if novel HotBalloon ablation
(HBA) was safe and effective compared with antiar-
rhythmic drug therapy (ADT) for the treatment of PAF.SEE PAGE 2758METHODS
This study was conducted as a prospectivemulticenter
randomized study of patients with drug-refractory
(resistant and/or intolerant to) symptomatic PAF
comparing treatment with HBA or ADT at 17 sites in
Japan.Written informed consentwas obtained from all
patients. This study protocol was in accord with the
Japanese good clinical practice guidance for medical
devices and approved by the institutional review
board at each site that participated in this study.
STUDY POPULATION AND DESIGN. Patients 20 years
of age or older and younger than 75 years of age who
were refractory to 1 ormore Class I to IV antiarrhythmic
drugs (AADs) were enrolled. Primary exclusion criteria
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received February 26, 2016; revised manuscript received SeptemAF; refractory to all of the following medications: pil-
sicainide, cibenzoline, propafenone, disopyramide,
and ﬂecainide; New York Heart Association functional
class III or IV; history of myocardial infarction or
unstable angina pectoris during the previous 6
months; comorbid severe ischemic heart disease,
valvular disorder, severe pulmonary hypertension,
carotid occlusion, or deep-vein thrombosis; use of
an LA appendage closure device, artiﬁcial heart valve,
pacemaker, implantable-cardioverter-deﬁbrillator or
implantable-electrocardiogram recorder, inferior vena
cava ﬁlter; and a history of cerebral infarction or
intracerebral bleeding with apparent neurological
symptoms during the previous 6 months.
Patients were randomized at a 2:1 ratio to HBA or
ADT. Two or more PAF episodes during the 6 months
before treatment (ablation or drug therapy) and 1 or
more episodes of PAF continuing for more than 30 s
recorded by electrocardiogram were required to be
enrolled. During the period between randomization
and the start of treatment, patients underwent ex-
amination. Patients with an LA diameter of 50 mm or
greater, a left ventricular ejection fraction of <35%, or
an LA thrombus were excluded.
PROTOCOL. Patients were evaluated at the clinical
site on day 0 to 7 and at 1, 3, 6, and 12 months after the
procedure in the HBA group, and on day 0 and at 1, 4,
and 10 months after the start of the drug-adjustment
period in the ADT group. Effectiveness was evaluated
in the 9-month effectiveness evaluation period after
an 84-day blanking period for the HBA group and
after a 28-day drug-adjustment period for the ADT
group. A 12-lead electrocardiogram was obtained at
all follow-up visits. Electrocardiogram monitoring
was performed using a portable electrocardiogram
monitor in both groups during the effectiveness
evaluation period. Patients were required to obtain
electrocardiogram readings at least once a week andpeaker honoraria and/or consulting fees from Boston
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CENTRAL ILLUSTRATION Fluoroscopic View of the Radiofrequency HotBalloon PV Ablation for Paroxysmal
Atrial Fibrillation Patients
Sohara, H. et al. J Am Coll Cardiol. 2016;68(25):2747–57.
(A) Left atriogram revealing (B) right superior PV balloon occlusion. The balloon material is very elastic and compliant, allowing single-shot ablation of PVs in the range
of 26 to 33 mm. (C) Scheme of PV antrum isolation using a radiofrequency HotBalloon catheter. LA ¼ left atrial; PV ¼ pulmonary vein.
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2749at the time of onset for any AF episodes. The 24-h
Holter monitoring was performed at 6 and 12
months (or the ﬁnal visit) after the procedure in the
HBA group, and at 4 and 10 months (or the ﬁnal visit)
after the start of the drug-adjustment period in the
ADT group. A 3-dimensional computed tomographyscanwas performed at baseline, and at 6 and 12months
after the procedure in the HBA group to detect any PV
stenosis. The stenosis rate was deﬁned as reduction
in diameter of >70%. All electrocardiograms and
3-dimensional computed tomography images were
masked and transmitted to an independent core
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2750laboratory for analysis. Adverse events were adjudi-
cated by the investigator at each site, and were
assessed by an independent evaluation committee.
The AADs were determined by the investigator using
Japanese antiarrhythmic guidelines.
HOTBALLOON ABLATION GROUP. The SATAKE
HotBalloon ablation system (Toray Industries, Inc.,
Tokyo, Japan) was composed of a 13-F balloon
catheter, an inner diameter 13-F deﬂectable guiding
sheath (Treswaltz, Toray Industries, Inc.), and a
radiofrequency generator that automatically controls
the temperature of the balloon and agitates the ﬂuid
inside the balloon. The system uses thermal energy
conducted by the heated balloon to ablate the tissue,
which does not directly mean radiofrequency abla-
tion. The balloon was inﬂated up to 26 to 33 mm in
diameter with contrast medium diluted 1:1 with
normal saline, at a recommended injection volume of
10 to 20 ml. A coil electrode mounted on the catheter
shaft within the balloon delivered radiofrequency
energy, and a thermocouple near the coil electrode
monitored the central balloon temperature. Radio-
frequency current of 1.8 MHz was delivered between
the coil electrode inside the balloon and the 4 cuta-
neous electrode patches on the patient’s back to
induce capacitive-type heating in the balloon. The
balloon’s central temperature was maintained at a
preset value (40C to 70C) by the generator’s auto-
matic regulation of radiofrequency energy output.
The agitation device delivered vibratory waves
through a catheter balloon lumen into the balloon to
mix the ﬂuid in the balloon to maintain a uniform
temperature throughout the balloon.
After transseptal puncture, a deﬂectable guiding
sheath was inserted into the LA by using a guidewire.
Subsequently, heparin was administered intrave-
nously tomaintain the activated clotting time between
300 and 400 s. Protamine was administered at the end
to reverse the heparin. Before ablation, the 4 PVs (right
superior, right inferior, left superior, left inferior) were
delineated by LA angiography through deﬂectable
guiding sheath, using contrast medium. PV potentials
in all veins were recorded using a mapping catheter
inserted through the deﬂectable guiding sheath. Sub-
sequently, the balloon catheter was inserted into the
LA using the deﬂectable guiding sheath.
The operator placed the balloon into the target PV
ostium by advancing the J-tip guidewire (Toray
Medical Co., Ltd.) through a catheter lumen into the
PV. Diluted contrast medium was injected into the
balloon through the catheter balloon lumen to inﬂate
the balloon. Balloon positioning in the PV was
adjusted by injection volume, so the balloon wouldcompletely appose to the PV wall and occlude the PV.
After ablation of the target PV ostium, the operator
inﬂated the balloon slightly as it apposed the PV
antrum, and repeated ablation. Subsequently, using
similar techniques the operator performed ablation
near the carina. After completion of all PV ablations,
the operator again inserted the mapping catheter into
the deﬂectable guiding sheath and recorded all PV
potentials. If PV potentials remained, the ablation
was repeated up to 3 times per location.
To prevent injury to the phrenic nerve, pacing of
the diaphragm from an electrode in the superior vena
cava was performed (especially during right PV abla-
tions). Ablation energy delivery was terminated if
diaphragmatic capture was lost. Furthermore, to
avoid damage to the esophagus, the esophageal
temperature was monitored (especially left PV abla-
tions) by applying Sensi Therm Esophageal Temper-
ature Monitoring System (St. Jude Medical, Inc., St.
Paul, Minnesota). If the temperature exceeded 39C,
cooling water was injected into the esophagus (8).
Intraoperative anticoagulation management and
anesthesia were performed according to the standard
practice of the clinical site. Postoperative anti-
coagulation was performed based on the judgment of
the operators using the most recent guidelines.
After the procedure, an 84-day blanking period
was set. The effectiveness evaluation period was
deﬁned as the 9 months after the end of the blanking
period (to 12 months after ablation).
ANTIARRHYTHMIC DRUG THERAPY GROUP. Patients
in the ADT group received treatment with AADs. A 28-
day drug-adjustment period was set to determine the
AADs to be used. The effectiveness evaluation period
was deﬁned as 9 months after the end of the drug-
adjustment period. Patients who experienced 30 s or
more of conﬁrmed AF (meeting the criteria for failure
of the effectiveness endpoints) within 3 months after
the end of the drug-adjustment period were allowed
to cross over to HBA treatment. Crossover data were
used only to investigate the safety of HBA.
RESTRICTIONS ON CONCOMITANT DRUGS AND
THERAPIES DURING THE STUDY. In the HBA group
during the effectiveness evaluation period, the use of
Classes I to IV AADs resulted in effectiveness failure
except for AADs to which patients were preopera-
tively determined to be refractory could be used at
the same or lower dose; and Class II and IV AADs
could be used for indications other than the treat-
ment of AF. In the ADT group, the use of AADs other
than those determined during the drug-adjustment
period resulted in effectiveness failure. Any of the
following resulted in effectiveness failure for patients
FIGURE 1 Patient Flow Diagram
153 enrolled and randomized
104 HBA group 49 ADT group
Total 134 patients received HBA
(HotBalloon only, one procedure only)
Excluded or withdrawn
(n=6)
Excluded or withdrawn
(n=4)
100 underwent HBA
18 discontinued
43 received ADT
40 discontinued
34 crossover group
After completed ADT group requirement,
underwent HBA
5 discontinued
Patients were randomized to HBA group or ADT group. Thirty-four of 40 patients who completed participation in the ADT group continued to
the crossover group (see Methods). ADT ¼ antiarrhythmic drug therapy; HBA ¼ HotBalloon ablation.
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2751in the HBA group: 1) LA ablation using other ablation
devices during the index procedure; 2) redo proced-
ures; 3) electrocardioversion during the effective-
ness evaluation period; or 4) undergoing a surgical
procedure or use of an implantable device that
might affect the evaluation of this study. Ablation or
3) or 4) above resulted in effectiveness failure for
patients in the ADT group.
EFFECTIVENESS ENDPOINTS. Acute success (PV
iso lat ion) . Success was deﬁned as a potential
#0.1 mV or no synchronization of the PV and LA
potentials.
Chronic success . The primary effectiveness
endpoint was chronic success, deﬁned as no docu-
mented AF episode continuing for 30 s or more,
regardless of the presence or absence of symptoms,
and no use of restricted concomitant drugs or thera-
pies. Patients who discontinued this study after the
start of ablation or the drug-adjustment period were
deﬁned as cases of treatment failure in both groups,
regardless of the reasons or timing.
Qual i ty of l i fe . Quality of life was investigated at
baseline and at the end of this study (or at study
discontinuation) using the 36-item Short-Form
Health Survey Version 2 Japan (SF-36v2).
Safety endpo ints . Serious adverse events (SAEs)
and major complications (MJCs) were investigated.
SAE was deﬁned as any untoward medical occurrence
that: 1) resulted in death; 2) was life threatening; 3)
resulted in disability (dysfunction affecting patient’snormal daily activity); 4) might result in disability; 5)
required or prolonged hospitalization for treatment; 6)
was as serious as the conditions mentioned in 1) to 5)
above; or 7) was a congenital disease or anomaly in the
offspring. MJC in the HBA group and the crossover
group was deﬁned as category 1) SAEs that occurred
within 7 days after the procedure; 2) all postoperative
severe PV stenosis (>70%) or esophageal perforation,
cardiac tamponade, phrenic nerve paralysis, or cere-
bral infarction accompanied by apparent neurological
symptoms; and 3) postoperative PV stenosis (#70%)
that required invasive treatment such as stenting or
was accompanied by severe clinical symptoms.
STATISTICAL ANALYSIS. A 2-tailed test was con-
ducted for hypothesis testing without multiplicity
adjustment with a signiﬁcance level of 5%. Intergroup
comparison by Fisher’s exact test was conducted for
the primary analysis of chronic success, the primary
effectiveness endpoint. In addition, the following
analysis was performed as an exploratory analysis. A
Kaplan-Meier curve was plotted for the time to ﬁrst
AF recurrence, use of restricted concomitant drugs,
and performance of restricted concomitant therapies;
and an intergroup comparison was conducted using a
log-rank test. We used Cox’s proportional hazard
model to estimate the hazard ratio and its Wald-type
95% conﬁdence interval (CI). Events that had
occurred during the blanking period and termination
were treated as those occurring at the ﬁrst day of the
evaluation period (day 0).
TABLE 2 Procedural Characteristics
HBA
(n ¼ 100)
HBA and
Crossover
(n ¼ 134)
Conscious sedation (patients) 99.0 99.3
Procedure time, min* 113.8  33.2
(n ¼ 99)
113.9  31.9
(n ¼ 133)
Ablation time, min† 28.0  4.4 28.4  4.6
Fluoroscopy time, min 49.5  27.4 49.4  26.6
Ablation time per PV, min
Right superior 8.1  2.1 8.3  2.2
Right inferior 4.5  1.0 4.4  0.9
Left superior 10.2  2.9 10.5  3.1
Left inferior 5.2  1.6 5.2  1.6
Number of ablations per PV
Right superior 3.5  0.7 3.5  0.8
Right inferior 2.1  0.4 2.1  0.4
Left superior 3.4  0.9 3.5  0.9
Left inferior 2.3  0.7 2.3  0.7
Volume in the balloon per PV, ml
Right superior 9.5  1.6 9.7  1.7
Right inferior 7.9  1.8 8.1  1.9
Left superior 10.1  2.0 10.2  1.9
Left inferior 8.8  1.6 8.9  1.6
Values are % or mean  SD. *From the time of transseptal puncture to the time of
protamine administration after ablation. †The sum of ablation time for each PV.
HBA ¼ HotBalloon ablation; PV ¼ pulmonary vein.
TABLE 1 Baseline Characteristics
HBA
(n ¼ 100)
ADT
(n ¼ 43)
HBA and
Crossover
(n ¼ 134)
Age, yrs 58.8  10.4 61.0  10.0 58.9  10.3
Male 80.0 81.4 82.1
AF duration, yrs 5.3  6.8
(n ¼ 97)
4.6  4.6
(n ¼ 41)
5.1  6.3
(n ¼ 130)
Hypertension 51.0 55.8 50.7
Diabetes 3.0 9.3 4.5
Hyperlipidemia 19.0 14.0 16.4
Coronary artery disease 3.0 4.7 3.7
History of atrial ﬂutter 18.0 14.0 17.9
CHADS2 score 0.8  0.9 0.9  1.0 0.8  0.9
LA diameter, mm 38.3  5.6 38.3  4.9
(n ¼ 42)
38.1  5.4
% Left ventricular
ejection fraction
66.7  6.1 66.5  6.5
(n ¼ 42)
66.0  6.4
LA volume, ml 66.5  30.1 65.2  24.5
(n ¼ 42)
66.8  30.2
Number of AADs* 1.4  0.8 1.2  0.8 1.4  0.8
AADs*
Pilsicainide 35.0 37.2 33.6
Cibenzoline 14.0 20.9 14.2
Propafenone 6.0 0.0 6.7
Disopyramide 2.0 0.0 1.5
Flecainide 6.0 0.0 6.7
Others 57.0 41.9 54.5
Refractory AADs*
Class I/III 79.0 67.4 76.1
Class II/IV only 15.0 9.3 12.7
SF-36v2
Role physical 45.8  12.7 47.1  10.0
Role emotional 47.3  11.2 48.1  9.5
Mental health 49.0  9.9 50.3  8.4
Role/social component
summary
45.7  13.2 48.3  12.3
Values are mean  SD or %. *Used at the time of signing the informed consent.
AADs ¼ antiarrhythmic drugs; ADT ¼ antiarrhythmic drug therapy; AF ¼ atrial ﬁbrillation;
CHADS2 ¼ congestive heart failure, hypertension, age 75 or older, diabetes, and stroke scale;
HBA ¼ HotBalloon ablation; LA ¼ left atrial; SF-36v2 ¼ 36-item Short-Form Health Survey
Version 2 Japan.
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2752For the SF-36v2, analysis of covariance was per-
formed using changes from baseline at the end of this
study or study discontinuation, with the baseline as a
covariate. SAS version 9.3 software (SAS Institute
Inc., Cary, North Carolina) was used.
RESULTS
PATIENT CHARACTERISTICS. A total of 153 patients
were enrolled, with 104 and 49 patients randomized
to the HBA group and the ADT group, respectively.
Four patients in the HBA group and 6 patients in the
ADT group did not receive ablation or start the drug-
adjustment period. As a result, interventional treat-
ment was performed in 100 patients in the HBA group
and 43 patients in the ADT group. Thirty-four patients(79.1%) in the ADT group continued to the crossover
group. Accordingly, a total of 134 patients underwent
HBA (Figure 1).
Baseline characteristics in the HBA group were
similar to those in the ADT group (Table 1). The mean
CHADS2 (congestive heart failure, hypertension, age
75 or older, diabetes, and stroke scale) score was <1 in
both groups, indicating that patients with a low risk
of embolism were enrolled.
PROCEDURAL CHARACTERISTICS. Procedural char-
acteristics are shown in Table 2. There was no patient
who could not undergo appropriate ablation because
of the anatomy of the PVs (i.e., form and diameter of
the openings of the PVs). Because the carina ablation
was counted as superior PV ablation, the duration and
number of ablations was greater for superior PVs than
for inferior PVs. The mean total ﬂuoroscopic time in
the HBA and crossover groups was 49.4  26.6 min
(minimum: 12 min; maximum: 132 min), and the mean
total duration of the procedure was 113.9  31.9 min
(minimum: 57 min; maximum: 215 min). Shorter
ﬂuoroscopic and procedure times were achieved by
the sites that had experience from previous HotBal-
loon studies.
EFFECTIVENESS OUTCOMES. Acute success (PV
iso lat ion) . Ablation in the HBA group resulted in
isolation of all 4 PVs in 93.0% (95% CI: 86.1 to 97.1; 93
TABLE 3 Effectiveness Outcomes of Radiofrequency HotBalloon PV Ablation
Acute HBA Success Rate
By patient By pulmonary vein
93.0% (93/100) 98.0% (392/400)
Chronic Success Rate†
HBA group ADT group p value*
59.0% (59/100) 4.7% (2/43) <0.001
*Fisher’s exact test. †Deﬁned as freedom from AF at 36-week effectiveness evaluation period.
Outcomes were achieved without using “touch-up” ablation using a conventional ablation
catheter.
Abbreviations as in Tables 1 and 2.
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was 98.0% (95% CI: 96.1 to 99.1; 392 of 400 PVs)
(Table 3).
Chronic success . The chronic success rate, the pri-
mary effectiveness endpoint, was 59.0% (95% CI:
48.7 to 68.7; 59 of 100) in the HBA group and 4.7%
(95% CI: 0.6 to 15.8; 2 of 43) in the ADT group, showing
a statistically signiﬁcant difference (p < 0.001)
(Table 3). All 7 patients with acute HBA failure resulted
in chronic failure.
The Kaplan-Meier plot with AF recurrence and the
use of restricted concomitant drugs or therapies as
events are presented in Figure 2. The event-free rates
at the end of the effectiveness evaluation period at
week 36 were 60.0% in the HBA group and 8.3% in the
ADT group, showing a statistically signiﬁcant differ-
ence (p < 0.001).
Qual i ty of l i fe . In the HBA group, 8 of 11 items
in the SF-36v2 quality-of-life form signiﬁcantly
increased at the end of this study or at study discon-
tinuation compared to baseline (Table 4). In the ADT
group, 9 of 11 items slightly decreased. The role
physical, role emotional, mental health, and role/
social component summary items signiﬁcantly in-
creased in the HBA group compared with those in the
ADT group.
SAFETY OUTCOMES. Adverse events were assessed
by the investigators and the independent evaluation
committee. There were no differences in assessment
results, other than for 1 event of cerebral infarction.
For 1 event of cerebral infarction, the independent
evaluation committee considered that the causal
relationship with HotBalloon could not be completely
ruled out, whereas the investigator did not consider it
to be related.
MJCs . The incidence of MJCs in all patients
undergoing HBA was 11.2% (95% CI: 6.4 to 17.8;
15 patients, 17 events) (Table 5). There was no
esophageal perforation, cardiac tamponade, cerebral
infarction which was classiﬁed as category 2 of MJC,
or PV stenosis which was classiﬁed as category 3
of MJC.
Phren ic nerve in jury . The incidence of phrenic
nerve paralysis was 3.7% (5 of 134). The events in the
5 patients were recovered within 9 to 13 months, and
inpatient hospitalization or prolongation of existing
hospitalization was not needed.
PV stenos is . The incidence of PV stenosis (>70%)
was 5.2% (7 of 134; 2 right superior PVs, 1 right inferior
PV, 1 left superior PV, 3 left inferior PVs). During the
follow-up period, no clinical symptoms associated
with PV stenosis were reported, and no invasive
treatments were required.Cerebra l infa rct ion . The incidence of cerebral
infarction was 1.5% (2 of 134). Two patients had onset
of cerebral infarction on the day of the ablation pro-
cedure. One patient had paralysis of the left upper
limb that resolved 2 days later and was attributed to
an air embolism during basket mapping catheter
insertion after ablation. The other patient had paral-
ysis of the right lower limb with a small cerebral
infarct area on magnetic resonance imaging that
resolved 27 days after the ablation procedure. The
patient had a background of patent foramen ovale,
and the investigator expressed the opinion that the
venous thrombus formed at the puncture site could
have entered the left heart system through the patent
foramen ovale.
SAEs . The incidence of SAEs was 10.4% (14 of 134
patients) in all patients undergoing HBA (Table 6) and
4.7% (2 of 43 patients) in the ADT group. For all
events, a causal relationship with the HotBalloon
catheter and/or AADs was ruled out by the investi-
gator. The independent evaluation committee
concluded that the causal relationship with the HBA
could not be completely ruled out for a case of cere-
bral infarction.
Adverse events . There was no occurrence of heart
wall perforation, cardiac tamponade, injury of a
coronary artery, valve, or chordae tendineae, atrial-
esophageal ﬁstula, or esophageal perforation. The
incidence of adverse events related to vascular ac-
cess sites whose causal relationship with the Hot-
Balloon catheter could not be ruled out was 20.9%
(28 of 134 patients); however, none of the events was
reported to be SAEs, and none required surgical
treatment or blood transfusion.
DISCUSSION
The main ﬁnding of this study is the demonstration of
the superiority of HBA compared with ADT in the
treatment of patients with PAF refractory to AADs.
FIGURE 2 Kaplan-Meier Plot of Time to the Events
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The events were ﬁrst atrial ﬁbrillation recurrence and use of restricted concomitant drugs or therapies. ADT ¼ antiarrhythmic drug therapy;
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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AF have reported signiﬁcant adverse events such as
PV stenosis requiring intervention, atrial-esophageal
ﬁstula, permanent phrenic nerve paralysis, pyloric
spasm, and death (1,4). None of the patients in this
study experienced these serious events.
EFFECTIVENESS OF HOTBALLOON ABLATION. The
single-procedure chronic success rate after 12 months
was 59.0% in the HBA group. This shows sufﬁ-
cient effectiveness, especially considering that the
procedures were performed by Japanese operators
with little balloon ablation experience. The chronic
success rates of other types of ablation catheters in
recent clinical studies have been reported to be
70% to 80% (3,4,9). These may reﬂect improved
treatment results due to the effect of the operator’s
experience with the ablation therapy being used. It
is expected that additional experience with HBA
will result in improved future outcomes. However,
comparison of effectiveness results among studies
must be performed carefully. In pivotal clinical trials
such as this one, AF recurrences are investigated
strictly compared with those occurring in many post-
marketing studies, and chronic success rates may
appear low. In fact, the single-procedure chronic
success rate of a well-established radiofrequencyablation method that served as the control device in
the HeartLight trial was 61.7% (10). The differences
in the protocols and the deﬁnition of success must
be noted.
The effectiveness comparisons among the initial
pivotal clinical trials experience are more accurate
than comparisons to post-marketing studies. The
chronic success rates reported were 63% in the
Thermocool AF trial including redo procedures (11);
65.8% in the SMART-AF (THERMOCOOL SMART-
TOUCH Catheter for the Treatment of Symptomatic
Paroxysmal Atrial Fibrillation) trial (12); 57.7% in the
STOP AF (Sustained Treatment of Paroxysmal Atrial
Fibrillation) trial (13); and 61.1% in the HeartLight trial
(10). In this study, weekly portable electrocardiogram
monitoring was performed, asymptomatic and short
episodes of AF ($ 30 s) were deﬁned as recurrence,
touch-up tools were not used and LA linear ablation
was not performed during ablation, and redo
procedures were not performed. In view of the above,
this study shows sufﬁcient effectiveness.
ANTIARRHYTHMIC DRUG THERAPY. The chronic
success rate in the ADT group was 4.7% in this study.
The event rate by Kaplan-Meier method was 7.3% in
STOP AF trial (13); 8.3% in this study; and 16.0% in
Thermocool AF trial (11). These results were similar.
TABLE 5 Tabulation of Major Complications
Category Type of Adverse Events
HBA and
Crossover
(n ¼ 134)
1 Serious adverse events within 7 days of
the ablation procedure (day 0-7)
Cerebral infarction 1.5 (2)
Complete atrioventricular block 0.7 (1)
Sick sinus syndrome aggravated 0.7 (1)
Pseudoaneurysm 0.7 (1)
2 PV stenosis (>70%) 5.2 (7)
Esophageal perforation 0
Cardiac tamponade 0
Phrenic nerve paralysis 3.7 (5)
Cerebral infarction accompanied with
apparent neurological symptom
0
3 PV stenosis (#70%) that meets 1 of
the following criteria:
requires an invasive intervention,
such as PV stenting;
results in clinically signiﬁcant symptoms
0
Total MJCs rate* 11.2 (15 patients,
17 events)
Values are % (number of events). *Total MJCs rate means the number of patients
experiencing MJC.
MJCs ¼ major complications; other abbreviations as in Tables 1 and 2.
TABLE 6 List of Serious Adverse Events in HBA Group and
Crossover Group
SAE Reported Term
Seriousness
Criteria
Time to Onset
From Ablation
Procedure
Cerebral infarction 5 0 day
Cerebral infarction 5 0 day
Complete atrioventricular block 5,6 0 day
Pseudoaneurysm 5 0 day
Sick sinus syndrome aggravated 5 2 days
Bradycardia 5 20 days
Loss of consciousness 4, 5 21 days
Cardiac failure acute 5 22 days
Coronary spastic angina (VSA) 5 22 days
Bladder cancer 5, 6 33 days
Sick sinus syndrome 5 73 days
Large intestine carcinoma 5 126 days
Acute bronchitis 5 166 days
Pneumonia 5 166 days
Gastric cancer 6 About 6 months
Anxiety neurosis 5 215 days
Total SAEs rate: 10.4% (14 patients, 16 events)*
Seriousness criteria are deﬁned as: 1) results in death; 2) is life threatening; 3)
results in disability (dysfunction affecting patient’s normal daily activity); 4) may
result in disability; 5) requires or prolongs hospitalization for treatment; 6) is as
serious as the conditions mentioned in events 1) to 5) above; 7) is a congenital
disease or anomaly in the offspring. *Total SAEs rate means the rate of patients
experiencing SAE(s) in HBA and crossover group (n ¼ 134).
HBA ¼ HotBalloon ablation; SAEs ¼ serious adverse events; VSA ¼ vasospastic
angina.
TABLE 4 Quality of Life (SF-36v2)
Scale
HBA
(n ¼ 100)
ADT
(n ¼ 32)
Differences
Between Groups
Physical functioning 1.9  0.9 1.3  1.7 3.2  1.9
p Value 0.048 0.434 0.099
Role physical 3.0  1.0 1.5  1.8 4.4  2.0
p Value 0.004 0.406 0.031
Body pain 1.1  0.9 0.4  1.7 1.4  1.9
p Value 0.260 0.826 0.456
General health
perceptions
2.4  0.7 0.3  1.2 2.1  1.4
p Value <0.001 0.800 0.129
Vitality 2.1  1.0 0.1  1.7 2.2  2.0
p Value 0.035 0.949 0.273
Social functioning 2.5  1.0 0.0  1.8 2.6  2.0
p Value 0.012 0.979 0.208
Emotional role 3.4  0.9 0.9  1.5 4.3  1.8
p Value <0.001 0.559 0.017
Mental health 2.7  0.9 1.0  1.6 3.8  1.9
p Value 0.004 0.539 0.049
Physical component
summary
0.8  0.7 0.5  1.3 1.3  1.5
p Value 0.273 0.691 0.376
Mental component
summary
1.6  0.9 0.3  1.6 1.3  1.8
p Value 0.065 0.849 0.455
Role/social component
summary
3.1  1.0 1.4  1.8 4.5  2.0
p Value 0.002 0.433 0.029
Values are least squares means of change from baseline  SE by analysis of
covariance.
Abbreviations as in Table 1.
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of AADs therapy in drug-refractory symptomatic PAF
patients has been reported to typically result in a 5%
to 20% chronic effectiveness success rate.
QUALITY OF LIFE. The SF-36v2 form, a comprehen-
sive quality of life scale not limited to some diseases
(14), has been widely used to evaluate symptom
change and symptomatic arrhythmia burden as an AF
ablation outcome. In this study, many items for pa-
tients in the HBA group improved signiﬁcantly
compared to their baseline values and the values of
the ADT group (Table 4), suggesting that HBA may not
only provide rhythm control but also decrease
symptoms and improve physical and mental health.
COMPLIANT BALLOON FITS VARIATIONS IN PV
ANATOMY. The HotBalloon material is compliant
enough to accommodate variations in PV anatomy. As
previously reported, compliance of the balloon
membrane also allows the device to be used to
perform a box isolation procedure for the treatment
of various types of AF (7).
The temperature of the ﬂuid in the HotBalloon
during radiofrequency energy delivery is not sus-
ceptible to the effects of the temperature of
the circulating blood in the surrounding vessel.
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Therefore, operators do not need to completely block
blood circulation to perform PV antrum and carina
ablation, and vein occlusion should be maintained
during ostial PV ablation. In addition, the size and
form of the HotBalloon can be altered. The balloon
expands from 26 to 33 mm in size with a recom-
mended injection volume of 10 to 20 ml. A single
balloon catheter can perform ablation in PVs of
various sizes and shapes. These factors demonstrate
the potential merit.
PULMONARY VEIN STENOSIS. In this study, 7
patients developed PV stenosis (>70%). All patients
with PV stenosis were asymptomatic, and no in-
terventions were required during the follow-up
period. Investigation of the ﬂuoroscopic images dur-
ing ablation for these 7 patients conﬁrmed a trend to-
ward the balloon being located deeper in the PV. It is
considered that distal PV ablation is a risk factor for
the development of PV stenosis. In addition, in all 7
patients, the ﬂuid volume injected into the PV ablation
balloon was 8 ml or less. When the ﬂuid volume in the
balloon is small, the balloon becomes smaller in
diameter and more prone to inadvertently advance
deeper into the PV. Even if the balloon is conﬁrmed to
be located at an appropriate site by radiography before
ablation, the balloon may inadvertently advance
deeper into the PV, such as by a sudden motion of a
patient during radiofrequency energy delivery.
Therefore, verifying proper balloon position using
radiography every 30 s during ablation and a higher
balloon injection volume (10 to 20 ml) are strongly
recommended. It is believed that mastering such skills
will lead to future reductions in the risk of PV stenosis.
ESOPHAGEAL INJURY. Although complications
related to esophageal injury have been reported with
other types of ablation catheters (15), there were no
symptomatic serious esophageal injuries using the
HotBalloon, including esophageal ulceration, pyloric
spasm, and atrial-esophageal ﬁstula detected.
The esophageal cooling method (8) performed intra-
operatively might contribute to the prevention of
these complications. The ability to immediately stop
ablation by deﬂating the balloon and immediately
reduce radiofrequency power and temperature in the
balloon also may contribute to the avoidance of
serious esophageal injury. However, it should be
noted that no routine endoscopy was performed;
therefore no data about the incident of esophageal
injury can be provided.
PHRENIC NERVE INJURY. Phrenic nerve injury is a
well-documented complication of ablation for AF(1–4,13). In this study there were 5 events of phrenic
nerve paralysis. However, all 5 patients recovered.
The HotBalloon does not adhere to the tissue, so
ablation can be immediately halted by ceasing radio-
frequency energy delivery and deﬂating the balloon.
This might be the reason that the 5 events were tran-
sient. However, despite this potential advantage,
efforts should be made to avoid phrenic nerve injury
during HBA. In these 5 patients, the balloon ﬂuid
volume during right superior PV ablation was 8 ml or
less. When the balloon is small in diameter, it is more
prone to inadvertently advance deeper into the PV,
increasing the risk of injury. In some cases the balloon
may advance into the distal portion of the right su-
perior PV beyond the cardiac border where the phrenic
nerve is typically immediately posterior to the
right atrium. Therefore, proper balloon position
within the cardiac shadow should be maintained
and the recommended balloon injection volume
should be used.
CEREBRAL INFARCTION. There were 2 events of
cerebral infarction in this study. One of them
occurred when, after ablation, a basket mapping
catheter was inserted in the sheath. During the
insertion, the sound of air sucked in the sheath was
heard and ST-segment elevation was detected. In the
other event, the investigator reported that the venous
thrombus formed at the puncture site could have
entered the left heart system through the patent
foramen ovale. However, with regard to the second
cerebral infarction, the independent evaluation
committee concluded that the causal relationship
with HotBalloon could not be completely ruled out.
The authors thought that these 2 events were
important “procedure-related SAE” as both of the
incidents occurred within 24 h after the procedure.
Although both events were fully resolved 2 and 27
days after the procedure, respectively, careful atten-
tion must be paid to the proper use of HotBalloon and
other devices, with proper care of puncture sites and
anticoagulation treatment.
STUDY LIMITATIONS. Although this trial was a pro-
spective multicenter randomized study, there were
several limitations to be considered. The evaluation
period was 48 weeks. A longer period trial should be
conducted in the future to investigate the effective-
ness and safety of the thermal properties of HBA.
There were no devices in widespread use that
were approved for PAF treatment in Japan at the
time (2011) of planning this study, so HBA was not
comparable with other ablation devices as controls.
In addition, the deﬁnitions of recurrence of AF and
of the chronic success were different in the trials for
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In patients with PAF, ablation is more effective than
ADT in maintaining sinus rhythm. HBA is superior to ADT in
maintaining sinus rhythm in patients with PAF.
TRANSLATIONAL OUTLOOK: Multicenter, randomized
studies are needed to assess the potential beneﬁts of compliant
HBA in patients with non-PAF.
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2757other ablation devices. The effectiveness of HBA
showed superiority to ADT, but it was difﬁcult
to simply compare the HBA with other ablation
devices.
In this trial, no routine esophageal endoscopy was
performed to investigate esophageal injury. In addi-
tion, the interpretation of the quality-of-life data is
limited due to the high crossover rate.
CONCLUSIONS
This clinical trial demonstrates the superiority of HBA
over ADT in the treatment of patients with PAF with a
favorable safety proﬁle.
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